A Controlled, Randomized, Open Label Phase II Trial to Evaluate Safety and Efficacy of a 1st Line Combination Treatment With Weekly Infusions of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG-1) in Three Dose Levels Compared With Gemcitabine Monotherapy in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

Trial Profile

A Controlled, Randomized, Open Label Phase II Trial to Evaluate Safety and Efficacy of a 1st Line Combination Treatment With Weekly Infusions of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG-1) in Three Dose Levels Compared With Gemcitabine Monotherapy in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Paclitaxel (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Sep 2009 Results presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
    • 17 Jun 2009 Efficacy and tolerability data presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009).
    • 01 Jun 2009 Results reported at the 11th World Congress on Gastrointestinal Cancer 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top